- Reversible Lansoprazole-Induced Interstitial Lung Disease Showing Improvement after Drug Cessation
-
Hwang KW, Woo OH, Yong HS, Shin BK, Shim JJ, Kang EY
- KMID: 1098197
- Korean J Radiol.
- 2008 Apr;9(2):175-178.
- doi: 10.3348/kjr.2008.9.2.175
Lansoprazole is an acid proton-pump inhibiting drug that is used for the treatment of duodenal or gastric ulcers, H. pylori infection, gastroesophageal reflux disease or Zollinger-Ellison syndrome. Although lansoprazole is... -
- CITED
-
- Close
- SHARE
-
- Close
- Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection
-
Lee NR, Jang JW, Kim HS, Yhim HY
- KMID: 2366019
- Korean J Intern Med.
- 2015 Jul;30(4):550-553.
- doi: 10.3904/kjim.2015.30.4.550
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma
-
Kang MH, Ju JH, Kim HG, Kang JH, Jeon KN, Kim HC, Lee GW
- KMID: 964727
- Korean J Intern Med.
- 2010 Dec;25(4):447-449.
- doi: 10.3904/kjim.2010.25.4.447
A 63-year-old female diagnosed with relapsed multiple myeloma visited our hospital complaining of a persistent cough. Since July 2006, she had been taking 100 mg thalidomide daily and gradually developed... -
- CITED
-
- Close
- SHARE
-
- Close
- Rituximab-CHOP Induced Interstitial Pneumonitis in Patients with Disseminated Extranodal Marginal Zone B Cell Lymphoma
-
Kim KM, Kim HC, Jeon KN, Kim HG, Kang JH, Hahm JR, Lee GW
- KMID: 2396100
- Yonsei Med J.
- 2008 Feb;49(1):155-158.
A 69-year-old male was diagnosed in February 2004 with stage IV extranodal marginal zone B cell lymphoma involving the mediastinal nodes, lung parenchyma and bone marrow with high LDH. Shortness... -
- CITED
-
- Close
- SHARE
-
- Close
- Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
-
Kang W, Kim JS, Cho SH, Kim SK, Chang J, Park MS
- KMID: 1074999
- Yonsei Med J.
- 2010 May;51(3):448-450.
- doi: 10.3349/ymj.2010.51.3.448
Bortezomib, an inhibitor of 26S proteosome, is recently approved treatment option for multiple myeloma. Thalidomide, a drug with immunomodulating and antiangiogenic effects, has also shown promise as an effective treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Interstitial Pneumonitis in a Patient with Chronic Hepatitis C and Chronic Renal Failure on Interferon Therapy
-
Kang EJ, Kim DK, Jeon SR, Choi HS, Jeong SW, Jang JY, Lee JS, Uh ST
- KMID: 1792815
- Korean J Gastroenterol.
- 2011 Jul;58(1):47-52.
- doi: 10.4166/kjg.2011.58.1.47
After 4-months of alpha interferon (IFN-alpha), a 64-year old woman with chronic hepatitis C developed a cough and dyspnea and showed diffuse infiltrative opacities on her chest X-ray. Her symptoms... -
- CITED
-
- Close
- SHARE
-
- Close
- Two Cases of Interstitial Pneumonitis Caused by Rituximab Therapy
-
Lee Y, Kyung SY, Choi SJ, Bang SM, Jeong SH, Shin DB, Lee JH
- KMID: 759845
- Korean J Intern Med.
- 2006 Sep;21(3):183-186.
- doi: 10.3904/kjim.2006.21.3.183
Rituximab, a chimeric monoclonal antibody directed against CD20, has become a part of the standard therapy for patients with non-Hodgkin's lymphoma either in combination with other drugs or as a... -
- CITED
-
- Close
- SHARE
-
- Close
- The First Successful Heart-Lung Transplant in a Korean Child with Humidifier Disinfectant-Associated Interstitial Lung Disease
-
Jhang WK, Park SJ, Lee E, Yang SI, Hong SJ, Seo JH, Kim HY, Park JJ, Yun TJ, Kim HR, Kim YH, Kim DK, Park SI, Lee SO, Hong SB, Shim TS, Choi IC, Yu J
- KMID: 2373684
- J Korean Med Sci.
- 2016 May;31(5):817-821.
- doi: 10.3346/jkms.2016.31.5.817
From 2006 to 2011, an outbreak of a particular type of childhood interstitial lung disease occurred in Korea. The condition was intractable and progressed to severe respiratory failure, with a... -
- CITED
-
- Close
- SHARE
-
- Close
- Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
-
Lim KH, Yoon HI, Kang YA, Lee KW, Kim JH, Bang SM, Lee JH, Lee CT, Lee JS
- KMID: 1785660
- Korean J Intern Med.
- 2010 Mar;25(1):86-92.
- doi: 10.3904/kjim.2010.25.1.86
BACKGROUND/AIMS: The aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus... -
- CITED
-
- Close
- SHARE
-
- Close
